Les Echos – SME-Regions / Innovators
September 2025

In early 2026, Atonco plans to launch a clinical trial for its drug candidate ATO-101, which could revolutionize the treatment of bladder cancer. The Nantes-based company, founded in 2021, is preparing to submit its application to the ANSM (French National Agency for the Safety of Medicines and Health Products) and has just raised €4 million to fund this new stage, bringing total fundraising since its inception to €10 million.

Reference

Source: Les Echos, SME-Regions / Innovators

Date: September 2025

Link to original article: www.lesechos.fr